Evaluation of a novel chemiluminescent immunoassay for autoantibody detection in pemphigus and bullous pemphigoid.

ABSTRACT:

Background

A novel fully automated chemiluminescent immunoassay (CLIA) has been developed to quantify autoantibodies specific for desmogleins (Dsg1, Dsg3), BP180, and BP230, key target antigens in pemphigus and bullous pemphigoid. This study aims to evaluate the diagnostic accuracy of the CLIA in diagnosing pemphigus and BP and its correlation with disease severity and clinical features.

Methods

Sera from 106 bullous pemphigoid and 54 pemphigus patients and control sera from 153 patients with other skin disease and 121 healthy volunteers were included. CLIA and BIOCHIP mosaic-based indirect immunofluorescence (IIFT-BIOCHIP) were performed for all bullous pemphigoid and pemphigus patients, with ELISA conducted for most. Disease severity was assessed using the Body Surface Are

SUBMITTER: Zhang N 

PROVIDER: S-EPMC12256432 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature